Competition Intensifies As Access Increases For US Biosimilars

AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals

 
• By Dave Wallace

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.

Five Paper Planes Colours
US biosimilars “will likely go from an average of three competitors to probably upwards of five in every single one of the existing therapeutic markets” • Source: Shutterstock

More from Biosimilars

More from Products